Physician profile
Laura Dutu
NPI 1659636967
$3,550.91
in general payments reported to CMS, 2019-2025
26 companies · $698 in 2025
The $698 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $172 · 2021: $250 · 2022: $488 · 2023: $817 · 2024: $675 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.58 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,656.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $345.31 | 2019-2025 | |
| Lilly USA, LLC | $284.38 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $275.23 | 2022-2024 | Freestyle Libre 3, Freestyle Insulinx, Freestyle Libre |
| Glaxosmithkline, LLC. | $199.78 | 2023-2024 | Shingrix, Arexvy |
| Exact Sciences Corporation | $127.09 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $83.49 | 2023-2025 | Repatha, Uplizna, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $83.38 | 2024-2025 | |
| Dynavax Technologies Corporation | $83.18 | 2023-2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals Lp | $59.51 | 2024-2025 | Farxiga |
| Alexion Pharmaceuticals, INC. | $44.86 | 2024 | Ultomiris |
| Corcept Therapeutics | $38.92 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.23 | 2024-2025 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $33.05 | 2025 | |
| Gilead Sciences, INC. | $22.79 | 2023 | Epclusa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $22.42 | 2024 | |
| Optinose US, INC. | $21.50 | 2025 | |
| Sanofi Pasteur INC. | $17.54 | 2023 | |
| Insightec,INC | $17.38 | 2025 | Exablate |
| Kyowa Kirin, INC. | $16.15 | 2024 | Crysvita |
| Pfizer INC. | $16.06 | 2025 | |
| Inspire Medical Systems, INC. | $15.78 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $14.35 | 2023 | Keveyis |
| Genentech USA, INC. | $13.64 | 2019 | |
| Abbvie INC. | $12.79 | 2022 | |
| Allergan, INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Dutu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.